Arcturus Therapeutics Announces Appointment of Ernst & Young LLP as the Company’s Independent Auditor
August 29, 2018 07:00 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (“Arcturus” or the “Company”) (NASDAQ: ARCT), a leading RNA medicines company, today announced that at the Company’s Annual...
Arcturus Therapeutics Appoints Andrew Sassine as Interim Chief Financial Officer
August 28, 2018 07:00 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company, today announced that it has appointed Andrew Sassine as Interim Chief...
Arcturus Therapeutics to Present at Three Investor Conferences in September
August 27, 2018 07:00 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company, today announced that Joseph E. Payne will present at the upcoming...
Arcturus Therapeutics Achieves Program Milestones and Refines Agreement with Cystic Fibrosis Foundation Therapeutics
July 23, 2018 07:00 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, July 23, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, today announced the achievement of key milestones as part of its agreement...
Arcturus Therapeutics Announces Annual and Extraordinary General Meeting of Shareholders to Be Held on August 24, 2018
July 20, 2018 17:23 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, July 20, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (“Arcturus” or the “Company”) (NASDAQ:ARCT), an RNA medicines company, today announced that it will hold an Annual and...
Arcturus Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
July 09, 2018 08:30 ET
|
Arcturus Therapeutics, Inc.
All Four Proposals Approved by Shareholders SAN DIEGO, July 09, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, today announced that at its...
Arcturus Therapeutics to Present at the JMP Securities Life Sciences Conference
June 18, 2018 04:00 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, June 18, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, today announced that it plans to present at the JMP Securities Life Sciences...
Arcturus Announces Management Appointments; Company Founder Joseph E. Payne Reinstated as President and CEO
May 31, 2018 07:00 ET
|
Arcturus Therapeutics, Inc.
Industry veteran Dr. Peter Farrell named as Chairman of the Board, Dr. Pad Chivukula reinstated as CSO and COO SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd....
Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders
May 30, 2018 22:32 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, May 30, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (“Arcturus” or the “Company”) (NASDAQ:ARCT), an RNA medicines company, today announced that the Extraordinary General Meeting...
Arcturus Therapeutics Comments on Court Ruling on Undisclosed Group Organized by Joseph E. Payne and his Associates in Violation of Regulation 13D
May 23, 2018 21:45 ET
|
Arcturus Therapeutics, Inc.
California Federal Court Rules that Arcturus is Likely to Succeed on Merits of its Claims Against Payne Further Violations by Payne and His Associates Enjoined to Permit all Arcturus Shareholders to...